University College Cork

Teagasc, the Agriculture and Food Development Authority

Artugen Therapeutics Ltd.

Other

Agriculture and Food Development Authority

Colin Hill

Paul Ross

Mary Rea

Ronald Farquhar

Paul Cotter

Desmond Field

Michelle O'Donnell

Brian Healy

Laurent Chesnel

Christopher K Murphy

Catherine Stanton

Stephen Hallahan

William Meaney

Ger Fitzgerald

Reynolds Paul Ross

Maire Philippa Ryan

Disclosed herein are compositions and methods for preventing, ameliorating, or treatinginfections and/or reducing the severity of one or more risk factors, signs, or symptoms associated withinfections. In particular, the technology of the present disclosure relates to methods for administering an effective amount of a composition comprising strains ofbacteria identified as ART24, ART4, and ART 12, to a subject suffering from or at risk forinfections.

Methods and compositions for the treatment of C. difficile

Disclosed herein are compositions and methods for preventing, ameliorating, or treatinginfections and/or reducing the severity of one or more risk factors, signs, or symptoms associated withbacteria identified as ART24, ART4, and ART 12, to a subject suffering from or at risk forinfections.

The disclosure relates to the live cultures of probiotic bacteria to treat infectious diseases in humans and animals. Food-grade or non-pathogenic cultures are used to treat localised infections.

Use of probiotic bacteria in the treatment of infection

A Nisin derivative or variant, comprising an amino acid substitution at amino acid position 29 in the amino acid sequence. The Nisin derivative exhibits enhanced antimicrobial activity when compared to wild type Nisin. The Nisin derivative has an application as a natural food additive and as a therapeutic agent.

Mutant Nisin ser 29 derivatives and the use thereof

The present invention relates to a nisin derivative comprising amino acid substitutions in the peptide sequence encoding the hinge region of the protein, wherein the derivative exhibits an increased anti-microbial activity.

Nisin derivatives and the use thereof

The present invention relates to a new bacteriocin, to microbial strains which can produce it and to uses of the bacteriocin and the strains. The bacteriocin is effective againstandamongst other organisms.

[object Object]

The invention provides a probiotic composition to alleviateinfection in farm animals. The composition may comprise at least one ofsub-species, and. The composition maybe formulated as an animal feedstuff, or as a pharmaceutical composition.

Probiotic composition suitable for animals

The production of a spray-dried bacteriocin lacticin 3147 powder is described. The powder is shown to have effective anti-microbial activity in a range of foodstuffs, namely infant milk formulations, powdered soup, yoghurt and cottage cheese. Increased anti-microbial activity was demonstrated when the lacticin 3147 powder was used in conjunction with increased hydrostatic pressure. The process comprises: inoculating a medium with a lacticin 3147-producing strain of bacteria, fermenting the inoculated medium, adjusting the pH of the fermentation to 6.3-6.7, inactivating the bacterial fermentate and evaporating the fermentate.

Growing community of inventors

Cork, Ireland

Colin Hill